Modality
Gene Therapy
MOA
BETi
Target
EZH2
Pathway
Apoptosis
Bladder CaOvarian Ca
Development Pipeline
Preclinical
~Aug 2011
→ ~Nov 2012
Phase 1
~Feb 2013
→ ~May 2014
Phase 2
~Aug 2014
→ ~Nov 2015
Phase 3
~Feb 2016
→ ~May 2017
NDA/BLA
Aug 2017
→ Sep 2029
NDA/BLACurrent
NCT05668839
393 pts·Ovarian Ca
2017-08→2029-09·Active
NCT03102639
1,042 pts·Ovarian Ca
2024-05→2028-01·Recruiting
1,435 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (2)
2028-01-021.8y awayPh3 Readout· Ovarian Ca
2029-09-243.5y awayPh3 Readout· Ovarian Ca
Trial Timeline
Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
NDA/BLA
Active
NDA/BLA
Recruit…
Catalysts
Ph3 Readout
2028-01-02 · 1.8y away
Ovarian Ca
Ph3 Readout
2029-09-24 · 3.5y away
Ovarian Ca
RecruitingActive|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05668839 | NDA/BLA | Ovarian Ca | Active | 393 | Safety |
| NCT03102639 | NDA/BLA | Ovarian Ca | Recruiting | 1042 | EDSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-179 | Johnson & Johnson | Approved | KRASG12C | |
| LLY-1592 | Eli Lilly | NDA/BLA | FGFR | |
| Sovarapivir | AbbVie | Phase 2/3 | IL-13 | |
| BAY-8733 | Bayer | Preclinical | AuroraA | |
| DSN-2247 | Daiichi Sankyo | NDA/BLA | EZH2 | |
| BII-1564 | Biogen | Phase 2 | PSMA | |
| Sovanaritide | Argenx | Phase 3 | TNFα | |
| HAL-9635 | Halozyme | Phase 2/3 | EZH2 | |
| 369-8021 | Hansoh Pharma | Approved | BTK | |
| COR-9456 | Corcept | Preclinical | TIGIT |